Advertisement


Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer

AACR Annual Meeting 2021

Advertisement

Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response to therapy. Clinicians may be able to personalize dietary interventions to optimize patient care.



Related Videos

Issues in Oncology

Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities

Ralph R. Weichselbaum, MD, of the University of Chicago, discusses oligometastasis as a part of the metastatic spectrum where ablative therapies, such as surgery or stereotactic body radiotherapy, may be curative alone or with systemic agents, as well as some potential biomarkers to guide treatment selection.

Breast Cancer
Immunotherapy

Rita Nanda, MD, on Triple-Negative Breast Cancer: Emerging Therapeutic Strategies

Rita Nanda, MD, of the University of Chicago, discusses the latest data on novel treatment strategies for triple-negative breast cancer, including immune checkpoint, PARP, and ATK inhibitors; antibody-drug conjugates; and targeting the androgen receptor.

Kidney Cancer
Immunotherapy

Brian I. Rini, MD, on Renal Cell Carcinoma: Data on Atezolizumab, Bevacizumab, and Sunitinib

Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (Abstract CT188).

Hepatobiliary Cancer

Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib

Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements (Abstract CT010).

Issues in Oncology

Joann G. Elmore, MD, MPH, on Cancer Diagnosis: When Pathologists Disagree, Artificial Intelligence May Help

Joann G. Elmore, MD, MPH, of the UCLA Fielding School of Public Health, discusses previous studies that show wide variability in cancer diagnoses, the uncertainties introduced by computer-aided detection tools, and new research on artificial intelligence and machine learning that may lead to more consistent and accurate diagnoses and prognoses, potentially improving treatment (Abstract SY01-03).

Advertisement

Advertisement



Advertisement